Monthly Archives: April 2012

Culture as a Culprit of the Pharma R&D Crisis
April 19, 2012

Everyone knows about the Pharma industry’s R&D productivity woes, but few seem to have solutions that work. Part of treating the problem requires an accurate diagnosis, and this winter’s work in Nature Reviews Drug Discovery by Scannell et al from

10 Comments

Biotech VC Returns: Diversified Funds vs. Healthcare-only Funds
April 9, 2012

Over the past decade biotech investments made by diversified venture capital firms have outperformed those by healthcare-focused firms.  Its unclear why the difference exists, but the historical data suggest it’s a striking differential. Examining the NVCA Benchmarking Database powered by

9 Comments